PPT-Demystifying Ruxolitinib: Identifying patients not responding nor tolerating ruxolitinib

Evolving landscape and what is on the horizon Andrew Kuykendall MD Moffitt Cancer Center Tampa Florida KuykendallMD Something my mother always told me There are many ways to fail Anemia. Patient with MF has Increasing . B. lasts, but Not . Y. et AML -- What to . D. o? . John Mascarenhas, MD. Myeloproliferative Disorders . Program. Tisch. . Cancer Institute, Division of Hematology/Oncology . Myeloproliferative. Neoplasms. January 20, 2012. November 16, 2011. FDA Indications for . Ruxolitinib. (. Jakafi. ). Intermediate or high-risk . Myelofibrosis. =80-90% of MF patients. JAK2V617F NOT required. Definition. 1 of 3 rare, Philadelphia-chromosome-negative myeloproliferative neoplasms (MPN) characterized by clonal stem-cell proliferation of red blood cells, white blood cells, and platelets. Polycythemia vera (PV). Definition. 1 of 3 rare, Philadelphia-chromosome-negative myeloproliferative neoplasms (MPN) characterized by clonal stem-cell proliferation of red blood cells, white blood cells, and platelets. Polycythemia vera (PV). myeloproliferative. . neoplasms. navigating the labyrinth. Elizabeth . Hexner. , MD, MSTR. Great Debates and Updates in Hematologic . Malignancies. April 26, 2014. Learning Objectives. Understand the . of Long Duration. Ruben A. Mesa, MD, FACP. Chair, Division of Hematology & Medical Oncology. Deputy Director, Mayo Clinic Cancer Center. Professor of Medicine. Co-Presenters. Jeffrey C. Bryan, . PharmD. Page 1 of 2 Format and content have been adapted where available with permission from M oun t Sinai H o spital RUXO - Version 1.0 RUXO (ruxolitinib) Diagnosis: Myelofibrosis Clinical Verification __________________________________________________________________ FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Jakafi is indicated for treatment of patients with intermediate or high-risk ruxolitinib : A Phase I study of ruxolitinib and umbralisib (TGR - 1202 ) in ruxolitinib - experienced myelofibrosis Tamara K . Moyo , Jeanne Palmer, Yi Huang, Olalekan Oluwole , Sanjay R . Moha Thedatawasretrospectivelyfrommedicalrecordsfor4patientswithacuteSRGvHDtreatedwithruxolitinib8patientswithchronicSRGvHDtreatedwithruxolitinib8pair-matchedpatientswithacuteSRGvHDtreatedwithetanerceptand with PV and . Debilitating . S. ymptoms on HU. Srdan Verstovsek, MD, PhD. Professor of . Medicine. Director. , . Hanns. A. . Pielenz. Clinical Research . Center for . Myeloproliferative . Neoplasms. David . Rosmarin. , MD. Tufts Medical Center, Boston, MA, USA. 关键信息. 白癜风是一种给患者带来沉重负担的常见疾病。. JAK. 抑制剂疗效广泛，非常适合治疗白癜风。. Clinical Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 Both clinical and laboratory ndings are required to make the diagnosis of MF. Characteristic bone marrow morphology i PMn - Iondon HMemMPo - Oncology FlinicMl AcuPe IeukMemiM s Mnd Myeloid NeoplMsms PMrP 4 : MyeloproliferMPive NeoplMsms January 2020 CONTENTS 1 FonPenPs Pan - London Haemato - Oncology Clinical Guide